Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 11/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421920 | 0.94 | EGFR (0.48) | EGFRBACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL29421946 | 0.93 | EGFR (0.52) | EGFRBACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL29350435 | 0.88 | BACE1 (0.53) | EGFRBACE1CTSDBACE2 | |
| SCHEMBL30140926 | 0.87 | EGFR (0.49) | EGFRBACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL29422024 | 0.87 | BACE1 (0.51) | EGFRBACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL29855833 | 0.87 | PTGS1 (0.52) | EGFRBACE1GLO1CTSDBACE2 | |
| SCHEMBL30170446 | 0.86 | EGFR (0.44) | EGFRGLO1PTGS1GSTK1 | |
| SCHEMBL29872215 | 0.85 | PTPN1 (0.50) | EGFRBACE1OPRD1CTSDPTPN1 | |
| SCHEMBL30563243 | 0.85 | DPP4 (0.45) | BACE1OPRM1OPRD1OPRK1GLO1 | |
| SCHEMBL29430832 | 0.85 | DPP4 (0.50) | EGFRBACE1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | EYEBIO KOREA (KR) | 2025-09-30 | — | — | US | disclosed |
| EP-4483959-A2 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-3974441-B1 | PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-10-24 | — | — | US | disclosed |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | VIP, FURIN, IAPP | EGFR 1108/4885BACE1 584/4885OPRM1 4051/4885 |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | EGFR 1239/4885BACE1 850/4885OPRM1 4016/4885 |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | EGFR 1239/4885BACE1 850/4885OPRM1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.